BPTH: 98% | Bio-Path Holdings shares are trading higher after the company announced the completion of its second dose cohort in Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia patients

THCH: 47% | TH International shares are trading higher after the company reported a year-over-year increase in Q4 financial results.

BNTC: 60% | Benitec Biopharma shares are trading higher. The company announced a $40 million oversubscribed private placement financing and reported interim clinical data for the first OPMD subject treated with BB-301 in its Phase 1b/2a study.